Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/9964
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13.
Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.
Administration, Inhalation | Animals | Antibodies, Neutralizing | Antibodies, Viral | Antiviral Agents | Female | Gene Expression | Humans | Lung | Male | Models, Molecular | Nasal Cavity | Neutralization Tests | Palivizumab | Pichia | Rats | Recombinant Proteins | Respiratory Syncytial Virus Infections | Respiratory Syncytial Viruses | Sigmodontinae | Single-Domain Antibodies | Viral Fusion Proteins | Viral Load | Virus
Files in this item
- GenerationAndCharacterizationO ...